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Recurrent respiratory tract infections (RRTIs) are the first leading cause of community- and
nosocomial-acquired infections. Antibiotics remain the mainstay of treatment, enhancing
the potential to develop antibiotic resistances. Therefore, the development of new alterna-
tive approaches to prevent and treat RRTIs is highly demanded. Daily sublingual adminis-
tration of the whole heat-inactivated polybacterial preparation (PBP) MV130 significantly
reduced the rate of respiratory infections in RRTIs patients, however, the immunologi-
cal mechanisms of action remain unknown. Herein, we study the capacity of MV130 to
immunomodulate the function of human dendritic cells (DCs) as a potential mechanism
that contribute to the clinical benefits. We demonstrate that DCs from RRTIs patients and
healthy controls display similar ex vivo immunological responses to MV130. By combin-
ing systems biology and functional immunological approaches we show that MV130
promotes the generation of Th1/Th17 responses via receptor-interacting serine/
threonine-protein kinase-2 (RIPK2)- and myeloid-differentiation primary-response gene-
88 (MyD88)-mediated signalling pathways under the control of IL-10. In vivo BALB/c
mice sublingually immunized with MV130 display potent systemic Th1/Th17 and IL-10
responses against related and unrelated antigens. We elucidate immunological mech-
anisms underlying the potential way of action of MV130, which might help to design
alternative treatments in other clinical conditions with high risk of recurrent infections.
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Introduction
Patients suffering from recurrent respiratory tract infections
(RRTIs) pose a major health-care problem with significant mor-
bidity and mortality affecting both children and adults, represent-
ing an important economic burden in Europe and USA [1–4].
RRTIs require repeated and prolonged antibiotic cycles, further
increasing the risk to develop antibiotic resistances [3, 5–7].
Humankind is entering into a “post-antibiotic era” with limited
treatment options that are causing many deaths yearly due to
life-threatening resistant pathogens [8, 9]. Negative factors asso-
ciated to the overuse of antibiotics also include deleterious effects
for the normal microbiome, which favour pathogen invasion and
subsequent bacterial and fungal superinfections [10, 11]. There is
an urgent need for new alternative approaches to antibiotics for
the prevention and treatment of RRTIs. Different types of mucosal
bacterial vaccines have received a lot of attention over the last
years as they significantly reduce the rate of infections in RRTIs
patients [3, 4, 12–14]. Bacterial vaccines containing soluble anti-
gens (bacterial lysates) administered through the oral route were
initially used to treat and prevent RRTIs [3, 12, 15, 16]. More
recently, polybacterial preparations (PBP) based on whole inac-
tivated components and delivered through the sublingual route
have been also studied as novel alternatives [3, 14]. The sublin-
gual PBP MV130 (Bactek) is one of these vaccines. MV130 is com-
posed of different proportions of whole heat-inactivated Gram-
positive and –negative bacteria often present in the nasal mucosa
and frequently involved in upper and lower respiratory infections
in Europe (60% Streptococcus pneumoniae, 15% Staphylococcus
aureus, 15% Staphylococcus epidermidis, 4% Klebsiella pneumoniae,
3% Moraxella catarrhalis and 3% Haemophilus influenzae) [14].
Clinical data showed that MV130 significantly reduced the rate
of infections in RRTIs patients, however, the immunological ways
of action remain elusive [3, 4, 14]. Both specific and nonspe-
cific mechanisms might well be involved in the observed clini-
cal benefits [3, 15–17]. In this study we exclusively focused on
the capacity of MV130 to immunomodulate human dendritic cells
(DCs) as potential antigen-independent mechanisms contributing
to the clinical benefits. We report that DCs from RRTIs patients and
healthy controls display similar ex vivo immunological responses to
MV130. By combining systems biology and immunological func-
tional experiments, we show that MV130 imprints human DCs
with the capacity to generate Th1, Th17 and IL-10-producing
T cells via receptor-interacting serine/threonine-protein kinase-
2 (RIPK2)- and myeloid-differentiation primary-response gene-88
(MyD88)-mediated signalling pathways under the control of IL-10.
In vivo data reveal that sublingual immunization of BALB/c mice
promotes potent systemic Th1/Th17 and IL-10 responses. Our
results provide novel insights into the immunomodulatory capac-
ity of MV130 on human DCs as a potential mechanism that in
cooperation with antigen-specific responses might well contribute
to the reported clinical benefits in patients suffering from RRTIs.
This study also uncovers that the employed methodology con-
stitutes a suitable strategy to elucidate immunological pathways
activated by specific PBPs at the molecular level, which might well
pave the way to develop more rational patient-tailored treatments
for many other clinical conditions at high risk of recurrent infec-
tions.
Results
MV130-activated human DCs produce
pro-inflammatory cytokines with high levels of IL-10
Nine patients suffering from RRTIs (8 females and 1 male, mean
age 52 ± 5; range 35–73) referred to the Clinical Immunology
Unit, Hospital Cĺınico San Carlos of Madrid and nine healthy con-
trols (8 females and 1 male, mean age 35 ± 4; range 22–51) were
recruited. All the patients included in the study had suffered RRTIs
defined as three or more episodes of upper or lower respiratory
tract infections or one pneumonia episode per year for more than
one year. None of the patients had previously received MV130
treatment. The detailed clinical features of the patients includ-
ing main diagnosis and routine therapy are collected in Table 1.
First, we quantified and compared the frequency of monocytes
and different DC subsets in peripheral blood from healthy subjects
and RRTIs patients. The percentage of myeloid DCs (mDCs) in
freshly isolated PBMCs was significantly lower in RRTIs patients
than in healthy subjects without significant changes in monocytes
or plasmacytoid DCs (pDCs) (Fig. 1A). Representative dot-plots
showing the gated cells in each case are also displayed. To assess
the capacity of MV130 to immunomodulate the function of human
DCs, we generated human monocyte-derived DCs (hmoDCs) from
healthy subjects and RRTIs patients and compared the cytokine
signature imprinted by this PBP. MV130- but not control-treated
hmoDCs produced significant increments of the pro-inflammatory
Th1- (IL-12p70 and TNF-α) and Th17-driving (IL-6, IL-1β, IL-23)
cytokines as well as high levels of IL-10 without significant dif-
ferences between DCs from healthy subjects and RRTIs patients
(Fig. 1B). Kinetic experiments revealed that IL-12p35/IL-12p40,
TNF-α, IL-6, IL-1β, IL-23 and IL-10 mRNA expression levels were
upregulated in MV130-activated hmoDCs in a time-dependent
manner up to 6 h (Supporting Information Fig. 1). Interestingly,
IL-10 mRNA levels were sustained after 24 h, suggesting that it
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Main diagnosis Routine therapy Infectious history Frequency
(episodes/
year)
# 1 F 39 Lymphangioleiomyo-
matosis.
MGUS.























None. URTIs since infancy.
LRTIs since infancy.
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LRTI: Lower Respiratory Tract Infection (bronchitis and pneumonia); URTI: Upper Respiratory Tract Infection; RUTI: Recurrent Urinary Tract
Infection.
MGUS: monoclonal gammopathy of unknown significance. IVIG: intravenous immunoglobulin.
could be involved in the downregulation of the other assayed pro-
inflammatory cytokines.
MV130-activated hmoDCs promote the generation of
Th1, Th17 and IL-10-producing T cells
To assess the capacity of MV130-activated hmoDCs to polarize
T cell responses, we performed co-culture experiments. MV130-
activated hmoDCs induced a significantly higher percentage of
proliferating allogeneic näıve CD4+ T cells than control-treated
hmoDCs without significant differences between healthy subjects
and RRTIs patients (Fig. 2A). MV130-activated hmoDCs from both
healthy controls and RRTIs patients generated T cells produc-
ing significantly higher levels of IFN-γ, IL-17A and IL-10 than
control-treated hmoDCs without IL-5 production and without
significant differences between groups (Fig. 2B). IL-4 was not
detected in cell-free culture supernatants in any assayed condition
(data not shown). Supporting these data, intracellular staining
experiments at the single cell level (Fig. 2C) demonstrated
C© 2017 The Authors. European Journal of Immunology published by
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Figure 1. MV130-activated hmoDCs from healthy subjects and RRTIs patients produce pro-inflammatory cytokines with high levels of IL-10.
(A) Percentage of monocytes (HLA-DR+ CD14+), mDCs (HLA-DR+ CD19− CD1c+ CD11c+) and pDCs (HLA-DR+ CD123+ CD303+) in freshly isolated
PBMCs from healthy donors (n = 9) and RRTI patients (n = 9). Data are pooled from three independent experiments with three donor and three
patient samples per experiment. Representative dot plots showing the gated cells are displayed on the right side. (B) Cytokines levels in cell-free
supernatants (IL-12p70, TNF-α, IL-6, IL-β, IL-23, and IL-10) quantified by ELISA after stimulation of hmoDCs from healthy subjects (n = 9) and
patients (n = 9) with Ctrl (control containing all excipients except the bacteria) or MV130 for 24 h. All data are represented as mean ± S.E.M.
Unpaired (for A) and paired (for B) t-test, *p < 0.05; **p < 0.01; ***p < 0.001.
that MV130-activated hmoDCs generate Th1/Th17 and IL-10-
producing T cells without significant induction of Th2 responses.
Interestingly, double intracellular staining experiments showed
that a significantly higher population of CD4+ T cells coexpress-
ing IFN-γ and IL-17A was generated by MV130-activated DCs than
control. However, we did not detect CD4+ T cells simultaneously
producing IFN-γ and IL-10 or IL-17A and IL-10 (Fig. 2D).
MV130-activated total blood DCs from healthy and
RRTIs patients show similar functional responses
We obtained an enriched fraction of total blood DCs containing
both mDCs and pDCs from PBMCs of healthy subjects and patients
suffering from RRTIs (Fig. 3A). The total blood DC fraction acti-
vated with MV130 produced higher levels of TNF-α, IL-6, IL-1β,
IL-23 and IL-10 than control-stimulated cells (Fig. 3B). Similar
responses were observed in total blood DCs from healthy subjects
and RRTIs patients for the assayed cytokines. Co-culture exper-
iments demonstrated that MV130- but not control-treated total
blood DCs from both groups also generated T cells producing high
levels of IFN-γ, IL-17A and IL-10 but not IL-5 (Fig. 3C).
To further assess the potential contribution of mDCs and pDCs
to the observed effects we obtained enriched fractions of both DCs
subsets from healthy donors (Fig. 4A and C) to assess cytokine
production after MV130 stimulation, including IFN-α responses in
pDCs. Enriched mDCs produced higher levels of all the assayed
proinflammatory cytokines and IL-10 after MV130 stimulation
than control (Fig. 4B). In contrast, pDCs only produced IL-6 after
MV130 stimulation (Fig. 4D). IFN-α production was only detected
after stimulation of enriched pDCs with TLR9-L as positive con-
trol but not after MV130 stimulation (Fig. 4E). Collectively, these
data indicate that mDCs are the main responder DC subset after
MV130 stimulation and suggest that although RRTI patients dis-
play lower percentages of circulating mDCs than healthy donors,
they are functional and might well play an important role in the
MV130 treatment for these patients.
Uncovering MV130-activated signalling pathways
in human DCs by global comparative transcriptomics
To gain insight into the underlying molecular mechanisms
involved in the effects imprinted by MV130 in human DCs, we
performed microarray genome wide expression analysis between
MV130- and control-treated hmoDCs. Considering that MV130
imprints the same responses in human DCs from healthy and
RRTIs patients, we employed hmoDCs from healthy donors. The
1456 genes were differentially expressed (FC > 2; p < 0.05) in
MV130-treated hmoDCs compared to control (Fig. 5A). Functional
enrichment analysis for the 750 up- and 706 down-regulated
genes by the gene ontology term biological processes showed
around 50% of them clustered in signal transduction, immune
responses and apoptotic biological processes (Fig. 5B). The rest of
up-regulated genes were mainly gathered in biological processes
related with immune system functions whereas down-regulated
genes in cell proliferation and signalling (Fig. 5B). Functional
gene set enrichment analysis of the 1,456 genes by Kyoto Ency-
clopedia of Genes and Genomes (KEGG) for pathways allowed
the identification of 10 immunoregulatory signalling pathways
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Figure 2. MV130-activated hmoDCs from healthy donors and RRTIs patients induce T cell proliferation and the generation of Th1, Th17 and
IL-10-producing T cells. (A) Representative dot plots of proliferating CFSE-labelled allogeneic naı̈ve CD4+ T cells after 3 days of co-culture with
hmoDCs from healthy subjects (n = 5) and patients (n = 5) in the presence of Ctrl or MV130. The frequency of proliferating cells is displayed inside
the plot. (B) ELISA quantification of IFN-γ, IL-17A, IL-5 and IL-10 cytokines in cell free supernatants produced by allogeneic naı̈ve CD4+ T cells
primed by Ctrl- or MV130-activated hmoDCs from healthy subjects (n = 9) and patients (n = 9) after 3 days. (C) Percentage of CD3+CD4+ T cells
producing IFN-γ, IL-17A, IL-4 and IL-10 generated after 3 days of co-culture of Ctrl- or MV130-activated hmoDCs from healthy donors and allogeneic
CD4+ T cells as determined by intracellular staining (n = 4–7). Representative dot plots are shown for each cytokine. (D) Percentage of CD3+CD4+ T
cells simultaneously producing IL-10 and IFN-γ, IL-10 and IL-17A, or IL-17A and IFN-γ after intracellular staining as determined by flow cytometry
analysis (n = 5). Panels B, C and D. Data are pooled from 3 to 5 independent experiments. Results are mean ± S.E.M. Wilcoxon-signed-rank test
*p < 0.05; **p < 0.01.
differentially activated in MV130-treated hmoDCs (Fig. 5C). A pre-
dicted network of interactions using as input the 49 non-redundant
genes clustered in the Janus kinase-signal transducer and activa-
tor of transcription (JAK-STAT), nucleotide-binding oligomeriza-
tion domain-like receptors (NLR) and Toll-like receptor (TLR) sig-
nalling pathways is shown (Fig. 5D). The predicted network sug-
gested that MV130 triggers TLRs and NLRs in human DCs leading
to the activation of NF-κB and the production of pro-inflammatory
cytokines, chemokines and IL-10. The interaction of cytokines and
chemokines with cognate receptors integrates JAK-STAT down-
stream signalling pathways that also could contribute to finely
tune immune responses in human DCs [18–20]. Interestingly, a
central role for IL-10 in the control of potential excessive pro-
inflammatory responses, for example, by inducing SOCS genes is
also predicted (Fig. 5D).
RIPK2-, MyD88-mediated pathways and IL-10 drive
immune responses in MV130-activated human DCs
To validate the pathways identified by global comparative tran-
scriptomic analysis, we performed inhibition experiments using
pepinh-MYD (an intracellular peptide blocking MyD88-mediated
signalling pathways coupled to TLRs) and Gefitinib (a selec-
tive pharmacological inhibitor of RIPK2, the adaptor protein for
NOD1/NOD2-mediated signalling pathways). The production of
TNF-α, IL-6, IL-1β, IL-23 and IL-10 by MV130-activated hmoDCs
was significantly impaired (inhibition up to 95%) by simultane-
ous preincubation with pepinh-MYD and Gefitinib (Fig. 6A). The
individual contribution of TLRs and NLRs for each cytokine is also
displayed. MV130 activated NF-κB in human DCs as determined
by the phosphorylation of IKKα/IKKβ at Ser176/Ser177 and IκBα
C© 2017 The Authors. European Journal of Immunology published by
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Figure 3. MV130-activated total blood DCs from healthy subjects and RRTIs patients produce pro- and anti-inflammatory cytokines and induce
Th1, Th17 and IL-10-producing T cells. (A) Representative dot plots of the different DC subsets contained in PBMCs from healthy subjects and RRTIs
patients and the obtained enriched total DC fraction in each case: pDCs (HLA-DR+ CD19− CD303+); mDCs (HLA-DR+ CD19− CD1c+). The percentage
for each DC subset is displayed inside the quadrants. Data are representative of three independent experiments. (B) Cytokine production by the
enriched total DC fraction from healthy individuals and patients after 24 h of stimulation with Ctrl or MV130 quantified by ELISA. Data are pooled
from three independent experiments (C) Cytokines produced by allogeneic naı̈ve CD4+ T cells primed by control- or MV130-activated total DCs
from healthy subjects and patients after 3 days quantified by ELISA. Results are the mean ± S.E.M. of three independent experiments.
at Ser32/36, which was totally abolished by simultaneous inhibi-
tion with pepinh-MYD and Gefitinib (Fig. 6B). Anti-IL-10 block-
ing antibodies (α-IL-10) significantly increased the production of
IL-12p70, TNF-α, IL-6, IL-1β and IL-23 in MV130-activated
hmoDCs at the protein level (Fig. 6C).
MV130 sublingual immunization induces Th1/Th17
and IL-10 mediated responses in mice
To study the in vivo relevance of our findings BALB/c mice were
sublingually immunized with MV130 or control excipients as
shown in Fig. 7A. Systemic responses were assessed after in vitro
stimulation of splenocytes isolated from MV130 or control immu-
nized mice as indicated in Fig. 7A. Spleen CD4+ T cells from both
MV130- or control-immunized mice showed significantly higher
proliferation rates when stimulated in vitro with MV130 than
control (Fig. 7B). Interestingly, spleen CD4+ T cells from mice
immunized with MV130 displayed significantly higher prolifera-
tion rates than those from control immunized mice after MV130
in vitro stimulation (Fig. 7B). Splenocytes from both groups stim-
ulated in vitro with MV130 produced significantly higher levels
of IFN-γ, IL-17A and IL-10 than those stimulated with control
excipients (Fig. 7C). Interestingly, the levels of IL-17A and IL-10
produced by splenocytes from mice sublingually immunized with
MV130 were significantly higher than those produced by spleno-
cytes from control mice after in vitro MV130 stimulation (Fig. 7C).
The levels of IFN-γ were also significantly high but without differ-
ences between groups (Fig. 7C). We did not detect production of
IL-5 in any of the assayed conditions (data not shown).
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Figure 4. Enriched mDCs produce proinflammatory cytokines and IL-10 after MV130 stimulation whereas enriched pDCs only IL-6. (A) Represen-
tative dot plots for mDCs contained in PBMCs and the obtained enriched mDCs (HLA-DR+ CD19− CD1c+ CD11c+). (B) Cytokine production by the
enriched mDCs after 24 h of stimulation with Ctrl or MV130 quantified by ELISA. (C) Representative dot plots for pDCs contained in PBMCs and
the obtained enriched pDCs (HLA-DR+ CD123+ CD303+). (D) Cytokines produced by the enriched pDCs after 24 h of stimulation with Ctrl or MV130
quantified by ELISA. Panels B and D: Data are pooled from 3 independent experiments. (E) IFN-α production by enriched pDCs stimulated for 24 h
with Ctrl, MV130 or TLR9-ligand as positive control. Results are the mean ± S.E.M. of three independent experiments.
To assess the capacity of MV130 to enhance systemic immune
responses also against unrelated antigens, mice sublingually
immunized with MV130 or excipients as control were challenged
in vivo with OVA and splenocytes collected to assess in vitro
OVA-specific immune responses as shown in Fig. 7D. Splenocytes
from mice that were sublingually immunized with MV130 and
subsequently challenged in vivo with OVA displayed significantly
higher proliferation rates after in vitro stimulation with OVA than
those from mice sublingually immunized with control excipients
(Fig. 7E). Remarkably, OVA-specific T cells from mice sublingually
immunized with MV130 produced significantly higher levels of
IFN-γ, IL-17 and IL-10 than those from the control group (Fig. 7F).
We did not detect significant differences in OVA-specific IgG1 or
IgG2a in the assayed conditions (data not shown). Collectively,
these data showed that sublingual immunization with MV130 also
significantly enhances Th1, Th17 and IL-10 immune responses
against the unrelated antigen OVA.
Discussion
In this preclinical study, we combined systems biology and func-
tional immunological approaches to demonstrate that MV130, a
sublingual PBP to treat and prevent RRTIs, imprints human DCs
with the capacity to generate Th1, Th17 and IL-10-producing T
cells via RIPK2- and MyD88-mediated signalling pathways under
the control of IL-10. We also showed that sublingual immuniza-
tion of BALB/c mice with MV130 induces systemic Th1, Th17 and
IL-10 responses in vivo against related and unrelated antigens.
Our data uncover the immunological mechanisms by which this
specific PBP immunomodulates the function of human DCs, which
in cooperation with antigen-specific responses might well also con-
tribute to the reported clinical benefits in patients suffering from
RRTIs. The understanding of these immunological mechanisms
might well help to the designing of rational patient-tailored novel
bacterial vaccines in other clinical conditions at high risk of recur-
rent infections.
RRTIs are the first leading cause of community- and
nosocomial-acquired infections. Antibiotics remain the mainstay
of treatment for RRTIs, but repeated and prolonged antibiotic
cycles in these patients enhance the potential to develop antibi-
otic resistances. That is why new alternative approaches to prevent
and treat RRTIs have brought a lot of attention over the last years.
At this regard, bacterial lysates from different species administered
through the oral route were initially employed and showed clini-
cal efficacy in the reduction of respiratory infections [3, 12, 13].
Compelling experimental evidence demonstrated that whole
inactivated bacteria induce more potent and durable responses
than soluble bacterial antigens or lysates [21, 22]. Nowadays, it
is well-recognized that sublingual immunization protects bacte-
rial components from gastrointestinal degradation and promotes
long-lasting immune responses locally and in distant target tis-
sues [23–26]. MV130 (Bactek), is a novel sublingual polybac-
terial vaccine that encompasses both features. It is composed
by whole heat-inactivated bacteria (90% Gram-positive and 10%
Gram-negative) causing the majority of respiratory bacterial infec-
tions in Europe and it is delivered through the sublingual route
[3, 4]. A pilot clinical study showed that daily sublingual admin-
istration of MV130 significantly reduced the rate of respiratory
infections in RRTIs patients [14], however, the immunological
mechanisms of action remained unknown. We studied the molec-
ular pathways underlying the potential capacity of MV130 to
immunomodulate the function of human DCs as an alternative way
of action of these preparations. The clinical benefits reported after
C© 2017 The Authors. European Journal of Immunology published by
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Figure 5. Global comparative transcriptome analysis by DNA microarrays of hmoDCs treated with control or MV130 for 24 h. (A) The Volcano
plot depicts −log10 of corrected p value versus log2 of fold-change (FC) for each gene. Moderate t-test analysis was used for n = 4 independent
experiments to find 1456 genes differentially expressed (FC > 2 and p < 0.05) between control and treated samples. Up- and down-regulated genes
are highlighted in red and blue, respectively. (B) GO term analysis using GeneCodis software was performed for the up- and down-regulated genes.
Altered GO terms at p < 0.05 and > 10 genes are displayed in red and blue chart diagrams for up- and down-regulated genes, respectively. (C)
KEGG analysis of the 10 altered (p < 0.06 and > 10 genes) immunoregulatory pathways analyzed with DAVID software according to the −log10
of corrected p value and the number of genes involved in each pathway. (D) Protein interaction network using as input the 49 non-redundant
genes from JAK-STAT, NLR and TLR signalling pathways with the STRING program at confidence of  0.7. The main clusters of associated genes
identified by the predicted network are indicated. Key molecules for each cluster are highlighted. The connected lines represent the associations
according to the color code indicated in the figure. Data are pooled from 4 independent experiments.
administration of mucosal polyvalent bacterial vaccines via the
sublingual route likely involve both antigen-specific and nonspe-
cific immunological and immunomodulatory effects [16, 17]. A
dense network of functional DCs playing a key role in the initiation
and maintenance of proper immune responses is located beneath
the human sublingual epithelium and tonsils [27–30]. Therefore,
we focused on the capacity of MV130 to immunomodulate the
function of DCs from patients suffering from RRTIs and healthy
subjects by analysing the immunological mechanism imprinted by
this PBP at the molecular level.
Our data revealed that MV130 promotes a potent pro-
inflammatory response, inducing the secretion of cytokines to
bias toward Th1 and Th17 responses, which might contribute to
enhance immune responses against intracellular and extracellu-
lar pathogens, respectively [31–34]. On the other hand, MV130
also induces the production of high levels of IL-10 by DCs and the
generation of IL-10-producing T cells, which is essential to avoid
excessive deleterious responses, to enhance pathogen clearance
and to keep tissue homeostasis [35–37]. Although the patients suf-
fering from RRTIs included in this study display fewer numbers of
mDCs than healthy subjects, MV130 was able to immunomodulate
DCs from both groups in a similar manner. Our data demonstrating
that BALB/c mice daily sublingually immunized with MV130 for
two weeks display potent systemic Th1, Th17 and IL-10 responses
C© 2017 The Authors. European Journal of Immunology published by
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Figure 6. MV130 immunomodulates human DCs’ function by mechanisms depending on NLR/RIPK2- and TLR/MyD88-mediated signaling path-
ways under the control of IL-10. (A) The graphs display the percentage of inhibition of TNF-α, IL-6, IL-1β, IL-23 and IL-10 production by MV130-treated
hmoDCs from healthy donors by the indicated inhibitors (Pepinh-MYD and/or Gefitinb) related to vehicle controls (Pepinh-Control and/or DMSO).
Results are pooled from 6–8 independent experiments. Mean ± S.E.M. is shown. Wilcoxon-signed-rank test *p < 0.05. (B) Western blot analysis of
protein extracts from hmoDCs stimulated for 30 min under the indicated conditions (Ctrl, MV130, Pepinh-MYD or Gefitinb) and quantification of
the reactive phosphorylated bands by scanning densitometry. Graphs in the right side represent the quantification of the corresponding reactive
bands (phospho-IKKα/IKKβ (Ser176/Ser177) and phospho-IkBα (Ser32/36)) with respect to the β-actin and relative to Ctrl-treated condition for each
case. One representative example out of 3 is shown. (C) Increase of IL-12p70, TNF-α, IL-6, IL-β and IL-23 cytokine production by MV130-activated
hmoDCs in the presence of specific blocking antibodies against IL-10 (α-IL-10) with respect to the levels in the presence of isotype control. Results
are pooled from six independent experiments. Mean ± S.E.M. is shown. Wilcoxon- signed-rank test *p < 0.05.
support the in vivo relevance of our findings. Remarkably, MV130
was also able to enhance in vivo immune responses against unre-
lated antigens such as OVA, suggesting the potential capacity
of this polybacterial preparation to confer protection not only
against the components included in the vaccine but also against a
broad range of different potential pathogens. Global comparative
transcriptome analysis by using DNA microarrays combined with
functional immunological in vitro experiments allowed us to
uncover that MV130 imprints human DCs with the capacity to
generate Th1/Th17 and IL-10-producing T cells by mechanisms
depending on RIPK2 and MyD88, key signalling and adaptor
molecules for NLRs and TLRs, respectively [38, 39]. DCs are
equipped with a large number of pattern recognition receptors
(PRRs) that enable them to link innate and adaptive immune
responses [28, 40–43]. Among them, NLRs and TLRs play essential
roles in regulating human DC function including their capacity to
polarize T cell responses [38, 39, 44–46]. Interestingly, our inhibi-
tion experiments using anti-IL-10 blocking antibodies established
the important role played by IL-10 produced by MV130-activated
DCs in the control of excessive immune responses. IL-10 drives key
immune regulatory functions by regulating different suppressive
mechanisms [34, 35, 47–49].
Collectively, we demonstrated that MV130, a sublingual whole
inactivated PBP that prevents infections in patients suffering from
RRTIs, directly acts on human DCs promoting the generation
of Th1/Th17 responses by mechanisms depending on NLR- and
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Figure 7. Induction of Th1, Th17 and IL-10 immune responses after in vivo MV130 sublingual immunization of BALB/c mice. (A) Scheme of the
sublingual immunization protocol and analysis of induced systemic responses. (B) Proliferation of CFSE-labelled CD4+ T cells from splenocytes
isolated from mice immunized sublingually with MV130 or control after in vitro stimulation with MV130 or control. (C) Cytokine production (IFN-γ,
IL-17A and IL-10) by splenocytes isolated from mice immunized sublingually with MV130 or control and stimulated in vitro with MV130 or control.
(D) Scheme of the immunization/challenge protocol followed to assess immune responses against the unrelated antigen OVA. (E) Proliferation
of CFSE-labelled CD4+ T cells from splenocytes isolated from the indicated mice after in vitro stimulation with OVA or control. (C) Cytokine
production by the indicated splenocytes stimulated in vitro with OVA or control. Results are mean ± S.E.M. of n = 6 (B), n = 3 (C), n = 8 (E) and
n = 6 (F) from two independent experiments. Ctrl, control containing all excipients except the bacteria; MV130, PBP Bactek. Unpaired or paired
t test, *p < 0.05; **p < 0.01; ***p < 0.001.
TLR-mediated signalling pathways under the control of IL-10.
We have recently shown that MV140, a sublingual PBP formu-
lated with a different composition of whole-inactivated bacteria
to treat recurrent urinary tract infections, also generates Th1,
Th17 and IL-10 immune responses [50]. Interestingly, the mecha-
nisms underlying the effects of MV140 (75% Gram-negative/25%
Gram-positive) depend on spleen tyrosine kinase (Syk)-mediated
signalling pathways in cooperation with MyD88 [50], which are
different to those reported in this study for MV130 (90% Gram-
positive/10% Gram-negative). Although TLRs contribute to the
final outcomes in both cases, the relative contribution in MV130
and MV140 is also different (Supporting Information Fig. 2). As
shown in this figure, the contribution of TLRs to the induction
of all the assayed cytokines, except for IL-6, was significantly
higher for MV130 than MV140 in human DCs. Overall, our data
uncover that although the clinical outcomes (significant reduc-
tion of recurrent infections in different clinical settings) seem to
be similar for different PBPs, the molecular mechanisms leading
to the immunomodulation and phenotypes underpinning clinical
benefits might completely differ depending on the specific bacte-
rial components in each PBP. The translation of this concept to
clinical practice might well pave the way to develop more rational
patient-tailored novel vaccines for many other clinical conditions
at high risk of recurrent infections, which might well also con-
tribute to combat the spread of antibiotic resistant infections.
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
190 Cristina Cirauqui et al. Eur. J. Immunol. 2018. 48: 180–193
Materials and methods
Media and reagents
RPMI 1640 (Lonza) supplemented with 10% fetal-bovine-serum,
100 μg/mL normocin, 50 μg/mL penicillin-streptomycin, 1% non-
essential aminoacids, 1% MEM-vitamins and 1 mM sodium pyru-
vate (cRPMI). PBP MV130 (Bactek)composed of heat-inactivated
bacteria (60% S. pneumoniae, 15% S. aureus, 15% S. epider-
midis, 4% K. pneumoniae, 3% M. catarrhalis and 3% H. influen-
zae), PBP MV140 (Uromune) composed of heat-inactivated bac-
teria (Escherichia coli, Proteus vulgaris, Klebsiella pneumoniae and
Enterococcus faecalis, 25% each) and control (all the excipients
without bacteria) were from Inmunotek S.L. Type B TLR9-ligand
(ODN 2006), inhibitors for MyD88 (Pepinh-MYD), RIPK2 (Gefi-
tinib) from InvivoGen and neutralizing anti-IL-10 (clone JES3-
9D7, Biolegend) were used.
Patients
The clinical features of the 9 patients suffering from RRTIs
included in this study are summarized in Table 1. The study was
approved by the Ethics Committee of Hospital Cĺınico San Carlos,
Madrid, Spain (C.P.-C.I.16/191-E TFG). Written informed con-
sent was obtained from all the subjects included in the study.
PBMC, human-monocyte derived dendritic cells
(hmoDCs), naı̈ve CD4+ T cells, total DC fraction and
cell cultures
PBMC from healthy donors and patients were isolated by Ficoll-
Paque Plus (GE-Healthcare) density gradient centrifugation from
heparinized blood as described [40, 43]. Monocytes were iso-
lated from PBMC with anti-human CD14 microbeads in autoMACS
(Miltenyi-Biotec) and cultured in RPMI medium with recombinant
human GM-CSF and IL-4 (100 ng/mL each; PeproTech). After 6
days, immature hmoDCs were harvested and phenotypically char-
acterized by flow cytometry. Näıve CD4+ T cells, total DC frac-
tion, enriched fractions of mDCs and pDCs were isolated with
“Näıve CD4+ T Cell”, “Blood DCs II”, CD1c (BDCA-1)+ and CD304
(BDCA-4/Neuropilin-1) Isolation Kits (Miltenyi-Biotec), respec-
tively. Immature hmoDCs, total blood DC, enriched mDCs and
pDCs (106 cells/mL) were stimulated with control or MV130 (107
bact./mL) for 24 h. The used dose of MV130 was selected based
on previous dose-depending titration experiments to be optimal
for the production of all the assayed cytokines. IL-12p70, TNF-
α, IL-6, IL-1β, IL-23 and IL-10 were quantified by ELISA. For
inhibition experiments, hmoDCs were preincubated for 6 h with
Pepinh-MYD (50 μM), 30 min with Gefitinb (5 μM) or 1 h with
anti-IL-10 (2.5 μg/mL) (or their corresponding controls) prior to
stimulation. HmoDCs or blood DC fraction were co-cultured with
purified allogeneic näıve CD4+ T cells (1:5 DC:T cell ratio) for 3
days in the presence of the control or MV130 (107 bact./mL) as
described [27, 28]. IFN-γ, IL-17A, IL-5 and IL-10 were quantified
by ELISA. For intracellular staining, the primed CD4+ T cells were
washed and re-stimulated with 25 ng/mL PMA plus 1 μg/mL ion-
omycin for 6 h and Brefeldin A (10 μg/mL) for last 4 h. Cells were
fixed, permeabilized and stained for IFN-γ, IL-17A, IL-4 and IL-10.
Purified allogeneic näıve CD4+ T cells were labelled with CFSE
(Molecular Probes) prior to co-cultures and proliferation assessed
in CFSE dilution experiments by flow cytometry.
Flow cytometry
Flow cytometry was performed at the UCM Cytometry and Flu-
orescence Microscopy Unit. Cells were washed with PBS/EDTA
2 mM/0.5% BSA and stained for 15 min at room temperature
with the fluorescence-labelled antibodies or corresponding iso-
type controls. The following anti-human monoclonal antibodies
(mAbs) were used for flow cytometry: fluorescein isothiocyanate
(FITC)-conjugated anti-CD1c, anti-HLA-DR, anti-CD123; allophy-
cocyanin (APC)-conjugated anti-HLA-DR; phycoerythrin (PE)-
conjugated anti-CD11c and anti-CD303; peridinin-chlorophyll-
protein (PerCP)-conjugated anti-CD14 and anti-CD4 (Myltenyi
Biotec). APC-conjugated anti-CD3; Alexa Fluor 488-conjugated
anti-IFN-γ and anti-IL-4 (BD Pharmigen). PE-conjugated anti-IL-
10 and anti-IL17A; PE/Cy7-conjugated anti-CD19 and Alexa488-
conjugated anti-IL-17A (BioLegend). For each staining, the corre-
sponding isotype controls (IgG2A-FITC, IgG1-PE, IgG2A-PerCP or
IgG1-APC) were also assayed.
Cytokine quantification
IL-12p70, TNF-α, IL-6, IL-1β, IL-10, IL-5, and IFN-γ in cell-free
supernatants were quantified using specific ELISA cytokine kits
(BD Biosciences); IL-23 using Human IL-23 ELISA Ready-SET-
Go! R© (e-Biosciences), IL-17A using Quantikine Elisa Kit (RD Sys-
tems) and IFN-α using VerikinTM ELISA kit (PBL assay science).
In all cases, manufacturer’s instructions of the specific kits were
followed with minor modifications. Briefly, the catching mAbs
were coated onto microtiter plates that were blocked with assay
diluent (PBS 1X with 5% FBS) and incubated with the stan-
dards or samples. After washing, biotinylated anti-human mAbs
and streptavidin-labelled peroxidase were added to detect bound
cytokines. After washing, chromogenic substrate (0.63 mg/mL
OPD, 0.03% H2O2 in 1 M sodium citrate) was added. The colour
reaction was stopped by adding 3N H2SO4 and the OD values were
measured at 492 or 450 nm according to each kit.
DNA microarray analysis
RNA was extracted using TRIZOL (Invitrogen) from hmoDCs from
healthy subjects stimulated with control or MV130 for 24 h. RNA
quality was measured with Agilent Bioanalyzer 2100 (Agilent
technologies) and only good quality samples, RIN (RNA Integrity
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Number) higher than 7.5, were selected for the analysis. Agilent
G4851B (8 × 60K) microarrays were used to analyze gene expres-
sion in 4 control- and 4 MV130-treated hmoDCs from healthy
donors. Agilent recommended protocol “Low Input Quick Amp
Labeling Kit, One-Color (G4140-90040)” was followed. Briefly,
200 ng of total RNA together with the appropriate RNA spike-
in (RNA Spike-In Kit, One-Color Agilent p/n 5188–5282) were
subjected to reversed transcription in the presence of T7-primer,
dNTPs, first strand buffer and enzymes for 2 h at 40°C. After-
wards cRNA was synthesized and Cy3-labelled in the presence
of transcription buffer, NTPs and T7-RNA Polymerase. Labelled
cRNA was purified using Qiagen columns (RNeasy Mini Kit). RNA
concentration was measured using the NanoDrop ND-1000 spec-
trophotometer and the yield and specific activity were determined.
600 ng of cRNA were hybridized to the microarray for 17 h at 65°C.
Fluorescence was measured using Agilent microarray scanner and
Feature Extraction software. Quality Control Report and spikes-
in were used to discard the microarrays that did not fulfill good
quality criteria. Gene Spring GX software (Agilent) was employed
for data normalization (75% percentile shift) and analysis. From
the original 60 K features microarray, 19 893 spots without flags
expressed in 90% of the samples were used for the following statis-
tical analysis. Differential gene expression assessment was carried
out using Moderate T test and Benjamini-Hochberg false discovery
rate for multiple correction. Selected genes showed a FC > 2 and
a p < 0.05. Transcript profiling: [ArrayExpress # E-MTAB-5259].
Gene set enrichment analysis was carried out by using Gene
Codis software web-based tool (http://genecodis.cnb.csic.es)
[51, 52] DAVID Bionformatics Resources 6.8 software
(https://david.ncifcrf.gov/) [53]. Protein interaction analysis was
performed with the STRING 10.0 (known and predicted protein-
protein interactions) free program (http://string-db.org/).
Western blot
Freshly isolated hmoDCs were previously pre-incubated with
Pepinh-MYD or Pepinh-control for 6 h and with Gefitinib or DMSO
for 30 min before the stimulation with control or MV130 for 30
min. Cell lysis was carried out with PBS/Triton 1% in the pres-
ence of 1 mM PMSF (Sigma), 1 μg/mL Leupeptin (Bachem) and
Aprotinin (Roche) for 30 min at 4 °C with vortex every 10 min.
Lysates were clarified by centrifugation at 10 000 × g for 15 min
at 4°C. Protein quantification was performed with Micro BCA Pro-
tein Assay Kit (Pierce) according to the manufacturer’s instructions
and samples with equal amounts of total protein were resolved in
10% SDS-PAGE. Proteins were then transferred to nitrocellulose
membranes.
The membranes were incubated with the following antibodies:
anti-human phospho-IkBα (Ser32/36) (1/1000, Cell signalling),
anti-human phospho-IKKα/IKKβ (Ser176/Ser177) (1/1000, Cell
signalling), and anti-human β-actin (1/5000, Sigma) as primary
antibodies and Goat anti-mouse or anti-rabbit conjugated with
horseradish peroxidase (1/2500, Pierce) as secondary antibodies.
Reactive bands were visualized by using ECL chemiluminescence
system (BioRad). Optical density of the reactive bands was quan-
tified with Fujifilm multigauge software and values expressed rel-
ative to β-actin loading control.
RNA extraction, cDNA synthesis, and quantitative
real-time RT-PCR
RNA was isolated from harvested cells using an RNeasy mini kit
(Qiagen) and cDNA generated using a PrimeScript RT reagent
Kit (Takara) according to manufacturers’ instructions. Real-
time quantitative PCR was performed on cDNA with FastStart
Universal SYBR Green Master (Rox) (Roche). The sequences
of the used pair primers were: Elongation Factor 1α (for-
ward, CTGAACCATCCAAT; reverse, GCCGTGTGGCAATCCAAT),
IL-12p35 (forward, ATGATGGCCCTGTGCCTTAGT; reverse, TGC-
CTCTTAGGATCCATCAGAAG), IL-12p40 (forward, GCATCT-
GTGCCCTGCAGTTA; reverse, CTTATTATCTTCCACTTTTCCTC-
CAAA), IL-6 (forward, GGTACATCCTCGACGGCATCT; reverse,
AGTGCCTCTTTGCTGCTTTCAC), IL-1β (forward, TTTTTGCT-
GTGAGTCCCGGAG; reverse, TTCGACACATGGGATAACGAGG),
IL-23 (forward, TCCCCATATCCAGTGTGGAGAT; reverse, GTG-
GATCCTTTGCAAGC) and IL-10 (forward, GTGATGCCCCAAGCT-
GAGA; reverse, CACGGCCTTGCTCTTGTTTT). Samples were run
on a real-time PCR system (ABI Prism 7900 HT; Applied Biosys-
tems). Data were normalized to Elongation Factor 1α (EF1α) and
displayed as 2−CT values multiplied by 104. CT was defined as
the difference between the cycle threshold value for the gene of
interest and Elongation factor 1α.
Mice experiments
Animal experiments were approved by the Ethics Committee of
Hospital Cĺınico San Carlos and Centro Nacional de Investiga-
ciones Cardiovasculares Carlos III (CNIC) and performed in accor-
dance with the Spanish national and international/EU legisla-
tion regulated by D.C.86/609/CEE; RD 1201/2005. BALB/c mice
(6-weeks-old) were sublingually immunized for 5 consecutive
days during two weeks with MV130 (109 bact./mL) or control
and sacrificed 2 days after the last immunization. For the experi-
ments to assess potential antigen-independent effects, mice were
intraperitoneally administered with 50 μg of OVA (EndoGrade,
Hyglos) 3 days after last sublingual administration and culled
after 9 days of the OVA challenge. Splenocytes were isolated fol-
lowing conventional protocols, labelled with CFSE and stimulated
in vitro with MV130 (107 bact./mL), OVA (50 μg/mL) or control.
Proliferation of CFSE-labelled CD4+ T cells was monitored by flow
cytometry after 5 days and cytokine production by Multiplex Cyto-
metric kits (eBioscience) after 48 h of stimulation.
Statistics
All data represent mean ± s.e.m. Unpaired or paired t-test for
differences between groups or Wilcoxon test when normality of
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data could not be inferred were performed with GraphPad Prism
software, version 6.0. Significance was defined as *p < 0.05,
**p < 0.01 and ***p < 0.001.
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